• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

    11/1/21 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKBA alert in real time by email

    CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare.

    AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)">

    "We are thrilled to welcome Ron to Akebia's Board of Directors and believe his experience driving improved patient outcomes and enabling access to healthcare for underserved populations will bring tremendous value to the Board," said John P. Butler, Chief Executive Officer, Akebia Therapeutics. "Ron's broad overall business experience strengthens our leadership capabilities. In addition, as kidney disease disproportionately impacts people of color, Ron's experience driving health equity in public policy and patient access will be critical expertise as Akebia works toward a brighter future for all people impacted by kidney disease." 

    Mr. Frieson has more than 20 years of experience managing business operations across a variety of sectors and geographies including healthcare, telecommunications and public policy. He held several leadership roles at CHOA before assuming his current role of COO, including President, Foundation and External Affairs, and Chief Public Policy Officer. Throughout his time with the organization, Mr. Frieson has been instrumental in improving Medicaid funding, increasing annual fundraising, and assessing the impact of the Affordable Care Act on pediatric healthcare systems.

    "Having spent over a decade fully immersed in healthcare system operations, I appreciate the complexities of access to care and the collaboration necessary to advance care," said Mr. Frieson. "I am honored to join the Board of Directors for Akebia, a company that is truly committed to patients."

    Mr. Frieson was a past chair and member of the American Kidney Fund's Board of Trustees. Prior to joining CHOA, Mr. Frieson was the Interim President and Chief Executive Officer of the Atlanta Urban League and formerly served as the Chief Diversity Officer of BellSouth Corporation (acquired by AT&T Inc. in 2006) where he created the Office of Diversity.

    About Akebia Therapeutics

    Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

    Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding: changes bringing value to the Company and Mr. Frieson's ability to influence the same. The terms "expect," "will," "confident," "expect," "plan," "continue," "potential," and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are not historical facts, but instead represent only Akebia's beliefs regarding future events, many of which, by their nature, are inherently uncertain and outside of Akebia's control. For a discussion of the risks related to the forward-looking statements in this press release see the "Risk Factors" section in Akebia's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, and other filings that Akebia may make with the U.S. Securities and Exchange Commission in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and, except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release. 

    Akebia Therapeutics® is a registered trademark of Akebia Therapeutics, Inc.

    Akebia Media Contact

    Mercedes Carrasco

    [email protected]  

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-appoints-ron-frieson-healthcare-operations-leader-to-board-of-directors-301412527.html

    SOURCE Akebia Therapeutics

    Get the next $AKBA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKBA

    DatePrice TargetRatingAnalyst
    4/28/2025$7.00Outperform
    Leerink Partners
    4/1/2025$6.00Buy
    Jefferies
    11/29/2023$4.00Buy
    BTIG Research
    8/28/2023$3.75Neutral → Buy
    H.C. Wainwright
    5/31/2023$2.00 → $4.00Neutral → Overweight
    Piper Sandler
    3/31/2022$10.00 → $2.00Buy → Neutral
    H.C. Wainwright
    3/31/2022Buy → Hold
    Needham
    3/31/2022$6.00 → $2.00Buy → Neutral
    Mizuho
    More analyst ratings

    $AKBA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership through $50 million underwritten public offering of common stock; cash and cash equivalents of $113.4 million as of the end of the quarter Akebia to Host Conference Call at 8:00 a.m. ET on May 8, 2025 CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) --  Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fir

      5/8/25 7:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 148,000 shares of Akebia's common stock on April 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $2.41 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of t

      5/1/25 4:15:00 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live webcast of the conference ca

      5/1/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Financials

    Live finance-specific insights

    See more
    • Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live webcast of the conference ca

      5/1/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

      Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conference Call at 8:00 a.m. ET on March 13, 2025 CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full year ended December 31, 2024 and recent business highlights. As previously announced, Vafseo® (vadadustat) shipments to customers began Januar

      3/13/25 7:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

      CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, March 13, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live web

      3/6/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/13/24 4:58:48 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/9/24 4:00:47 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/10/23 1:08:17 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Butler John P. sold $84,928 worth of shares (46,409 units at $1.83), decreasing direct ownership by 2% to 2,557,921 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      3/4/25 5:05:06 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Chief Medical Officer Burke Steven Keith sold $13,074 worth of shares (7,144 units at $1.83), decreasing direct ownership by 0.88% to 809,090 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      3/4/25 5:04:33 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Butler John P. was granted 701,000 shares and sold $302,925 worth of shares (144,250 units at $2.10), increasing direct ownership by 27% to 2,604,330 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      2/4/25 5:54:18 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Akebia Therapeutics with a new price target

      Leerink Partners initiated coverage of Akebia Therapeutics with a rating of Outperform and set a new price target of $7.00

      4/28/25 8:36:09 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Akebia Therapeutics with a new price target

      Jefferies initiated coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $6.00

      4/1/25 9:03:14 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research resumed coverage on Akebia Therapeutics with a new price target

      BTIG Research resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $4.00

      11/29/23 7:10:25 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

      Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

      3/28/24 10:46:38 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Leadership Updates

    Live Leadership Updates

    See more
    • Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

      CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeut

      1/9/24 8:30:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

      CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt

      11/1/21 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Akebia Therapeutics Inc.

      10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)

      5/8/25 7:29:11 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

      5/8/25 7:04:15 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Akebia Therapeutics Inc.

      SCHEDULE 13G - Akebia Therapeutics, Inc. (0001517022) (Subject)

      4/30/25 10:57:38 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care